ADTX Aditxt, Inc.
USHealthcareAs of 2026-07-10 11:36
Why ADTX matters now
Aditxt, Inc. (ADTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.00 with -9.09% on the session and $134.00 in market capitalization; recent performance reads 1-month -99.34% and YTD -99.99%.
The latest financial table shown here is Q1 2026, with revenue of $12.2K, net income of $-15.9M, and EPS of $-790.49. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5545612.5%.
The latest indexable market news headline is "Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million" from Business Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $1,280.00; recent insider activity includes DRW Securities, LLC filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.02
EV/EBITDA
-0.08
DCF Value
$5,101.15
FCF Yield
-5545612.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
19.9%
Operating Margin
-127821.4%
Net Margin
-362385.7%
ROE
926.0%
ROA
-373.6%
ROIC
-406.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $12.2K | $-15.9M | $-790.49 |
| Q4 2025 | $425.00 | $-4.7M | $-148.00 |
| FY 2025 | $3.2K | $-41.7M | $-1,153.83 |
| Q3 2025 | $748.00 | $-24.0M | $-548.78 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$1,280.00
Target (Median)
$1,280.00
Target Range
$1,280.00 - $1,280.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.81
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.